首页> Leukemia> Radioimmunotherapy in relapsed/refractory mantle cell lymphoma patients: final results of a European MCL Network Phase II Trial.

Radioimmunotherapy in relapsed/refractory mantle cell lymphoma patients: final results of a European MCL Network Phase II Trial.

导出原文传递

翻译打印收藏纠错

第一作者： S,Ferrero

第一单位： Department of Medicine III, University Hospital Großhadern/LMU, München, Germany.;Division of Hematology, Department of Molecular Biotechnologies and Health Sciences, University of Torino, Torino, Italy.

作者： S,Ferrero ^[1] ; A,Pastore ^[2] ; C W,Scholz ^[3] ; R,Forstpointner ^[2] ; A,Pezzutto ^[4] ; L,Bergmann ^[5] ; L,Trümper ^[6] ; J,Finke ^[7] ; U,Keller ^[8] ; P,Ghione ^[9] ; R,Passera ^[10] ; W,Hiddemann ^[2] ; O,Weigert ^[2] ; M,Unterhalt ^[2] ; M,Dreyling ^[2]

作者单位： Department of Medicine III, University Hospital Großhadern/LMU, München, Germany.;Division of Hematology, Department of Molecular Biotechnologies and Health Sciences, University of Torino, Torino, Italy. ^[1] Department of Medicine III, University Hospital Großhadern/LMU, München, Germany. ^[2] Department of Oncology and Hematology, Vivantes Klinikum, Berlin, Germany. ^[3] Charité University Medicine, Department of Hematology and Oncology, Berlin, Germany. ^[4] Medical Clinic II, University Hospital, Frankfurt, Germany. ^[5] Department of Hematology and Oncology, Georg-August Universiität, Göttingen, Germany. ^[6] Hematology/Oncology, University Medical Center, Freiburg, Germany. ^[7] III Medical Department, Technische Universität München, Munich, Germany. ^[8] Division of Hematology, Department of Molecular Biotechnologies and Health Sciences, University of Torino, Torino, Italy. ^[9] Biostatistician, Division of Nuclear Medicine, Città della Salute e della Scienza, University of Torino, Torino, Italy. ^[10]